Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| SEPTERNA | 3 | 16 | -3,97 % | ||
| UPSTREAM BIO | 3 | - | -2,66 % | ||
| UNITED THERAPEUTICS | 1 | 8 | -0,02 % | ||
| GILEAD SCIENCES | 1 | 5 | -0,33 % | ||
| RHYTHM PHARMACEUTICALS | 1 | 3 | +1,91 % | ||
| EVOLUS | 1 | 3 | +6,04 % | ||
| VIATRIS | 1 | 2 | +0,59 % | ||
| DEFINIUM THERAPEUTICS | 1 | - | -1,54 % | ||
 | UROGEN PHARMA | 1 | - | -1,63 % | |
| BIOGEN | - | 54 | +0,06 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05:54 | Quant snapshot: Impala Platinum, Turkcell Iletisim lead strong buys as Evolus lag | 4 | Seeking Alpha | ||
| So | Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity | 4 | GlobeNewswire (USA) | ||
| So | H.C. Wainwright Raises United Therapeutics (UTHR) Target to $600 | 2 | Insider Monkey | ||
| So | Upstream Bio presents additional Phase 2 data for verekitug | 4 | Investing.com | ||
| So | Septerna's SEP-631 shows positive Phase 1 trial results | 1 | Investing.com | ||
| So | UroGen vor Bewährungsprobe: ZUSDURI-Markteinführung im Fokus der Quartalszahlen | - | Investing.com Deutsch | ||
| So | Upstream Bio: Positive Phase-2-Daten für Verekitug, Aktie dennoch unter Druck | 1 | Investing.com Deutsch | ||
| So | Septerna meldet positive Ergebnisse der Phase-1-Studie für SEP-631 | 4 | Investing.com Deutsch | ||
| So | Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting | 2 | GlobeNewswire (USA) | ||
| So | Septerna, Inc.: Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy | 2 | GlobeNewswire (USA) | ||
| So | Notable healthcare headlines for the week: Viatris, Novo Nordisk, and Gilead Sciences in focus | 42 | Seeking Alpha | ||
| Erste Psilocybin-Behandlungen laufen - warum steht Optimi noch bei Pennystock-Level?! | Suneal Sandhu | ||||
| So | Arcellx: EPS übertrifft Schätzungen um 0,02 $ - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| Sa | Erasca, Inc. (ERAS): A Bull Case Theory | 2 | Insider Monkey | ||
| Sa | MannKind Corporation (MNKD): A Bull Case Theory | 5 | Insider Monkey | ||
| Sa | Wave Life Sciences Ltd. (WVE): A Bull Case Theory | 3 | Insider Monkey | ||
| Sa | Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory | 13 | Insider Monkey | ||
| Sa | Harrow, Inc. (HROW): A Bull Case Theory | 2 | Insider Monkey | ||
| Sa | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | 1 | GlobeNewswire (USA) | ||
| Sa | Why are Analysts Optimistic About Adaptive Biotechnologies (ADPT)? | 3 | Insider Monkey |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.